Asarina Pharma: Short-term Delay in Tourette’s Study - Redeye
Bildkälla: Stockfoto

Asarina Pharma: Short-term Delay in Tourette’s Study - Redeye

The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2021 due to an administrative backlog at public authorities.

Börsvärldens nyhetsbrev
ANNONSER